OPT - Additional $50M Funding to Advance Phase 3 Clinical Trials and Pre-commercialization Activities

2023-12-27 07:39:10 ET

DENVER, Colo., Dec 27, 2023 ( www.247marketnews.com )- Opthea Limited (NASDAQ: OPT) reported, this morning, that it expects to receive the remaining US$35 million committed funds under the Development Funding Agreement with Carlyle and Abingworth, and has entered into binding documentation with a new co-investor under an Amended DFA to secure an additional US$50 million in funding, which is non-dilutive to shareholders and no equity issued to Carlyle, Abingworth or the new co-investor

Opthea Limited is trading at $3.05 up $0.53 (+24.49%), on 224K shares traded.

Its 52-week range is $1.60 to 6.09. It’s made a strong move to bounce off 52-week low in October and today’s volume will set a new 52-week high.

24/7 MARKET NEWS, INC Disclaimer

24/7 …

The post Additional $50M Funding to Advance Phase 3 Clinical Trials and Pre-commercialization Activities appeared first on 24/7 Market News .

For further details see: